People born with a rare genetic mutation are unable to feel pain, but previous attempts to recreate this effect with drugs have had surprisingly little success. Using mice modified to carry the same mutation, UCL researchers funded by the MRC and Wellcome Trust have now discovered the recipe for painlessness.
‘Channels’ that allow messages to pass along nerve cell membranes are vital for electrical signalling in the nervous system. In 2006, it was shown that sodium channel Nav1.7 is particularly important for signalling in pain pathways and people born with non-functioning Nav1.7 do not feel pain. Drugs that block Nav1.7 have since been developed but they had disappointingly weak effects.
The new study, published in Nature Communications, reveals that mice and people who lack Nav1.7 also produce higher than normal levels of natural opioid peptides.
To examine if opioids were important for painlessness, the researchers gave naloxone, an opioid blocker, to mice lacking Nav1.7 and found that they became able to feel pain. They then gave naloxone to a 39-year-old woman with the rare mutation and she felt pain for the first time in her life.
“After a decade of rather disappointing drug trials, we now have confirmation that Nav1.7 really is a key element in human pain,” says senior author Professor John Wood (UCL Medicine). “The secret ingredient turned out to be good old-fashioned opioid peptides, and we have now filed a patent for combining low dose opioids with Nav1.7 blockers. This should replicate the painlessness experienced by people with rare mutations, and we have already successfully tested this approach in unmodified mice.”
Broad-spectrum sodium channel blockers are used as local anaesthetics, but they are not suitable for long-term pain management as they cause complete numbness and can have serious side-effects over time. By contrast, people born without working Nav1.7 still feel non-painful touch normally and the only known side-effect is the inability to smell.
Opioid painkillers such as morphine are highly effective at reducing pain, but long-term use can lead to dependence and tolerance. As the body becomes used to the drug it becomes less effective so higher doses are needed for the same effect, side effects become more severe, and eventually it stops working altogether.
“Used in combination with Nav1.7 blockers, the dose of opioid needed to prevent pain is very low,” explains Professor Wood. “People with non-functioning Nav1.7 produce low levels of opioids throughout their lives without developing tolerance or experiencing unpleasant side-effects. We hope to see our approach tested in human trials by 2017 and we can then start looking into drug combinations to help the millions of chronic pain patients around the world.”
Read more: GM mice reveal the secret to a painless life
The Latest on: Pain relief
via Google News
The Latest on: Pain relief
- Treatment that reduces PTSD should be allowed to be used by more veterans: lawmakeron June 27, 2020 at 10:30 am
Today is National PTSD Awareness Day. The urgency behind passing the bill is the link between PTSD and suicides, Rep. Scott Perry said. Up to 20 veterans a day commit suicide.
- His anemia was followed by searing foot pain. Seventeen years later, in precarious shape, a stellar athlete learned what was wrong.on June 27, 2020 at 8:00 am
A specialist’s blunt questions exposed the prolonged failure to diagnose and treat an elementary school principal for a disease that could have killed him.
- Chronic Pain Treatment Market 2020 Growth Probability, Key Vendors and Future Scenario Up To 2026on June 26, 2020 at 5:56 am
A recent report provides crucial insights along with application based and forecast information in the Global Chronic Pain Treatment Market. The report provides a comprehensive analysis of key factors ...
- Topical Pain Relief Market to Reach $13,276 million by 2025 at 7.4% CAGR, Says AMRon June 24, 2020 at 5:37 pm
According to the report published by Allied Market Research, the topical pain relief market was valued at $7,481 million in 2017, and is expected.
- Newsday Live: Lower Back Pain – Prevention and Treatmenton June 24, 2020 at 10:27 am
Join us for an informative talk from Dr. Shaheda Quraishi from Northwell Health who specializes in the treatment of spinal disorders including radiculopathy (sciatica), spondylosis (arthritis), and my ...
- Opioid Receptors Inside Cells Important for Pain Reliefon June 22, 2020 at 7:13 am
Activation of delta opioid receptors inside cells is important for the relief of inflammatory pain, researchers report.
- Tips for Chronic Pain Reliefon June 20, 2020 at 9:24 am
Chronic pain is generally thought of as pain that lasts longer than three months. Chronic pain is different from the acute pain you might have immediately after an accident or injury. It can occur in ...
- This CBD balm provides immediate relief for my shoulder, neck, and back painon June 20, 2020 at 2:48 am
While working from home, my posture has gotten worse and so has my neck and back pain. This Lord Jones CBD balm relieves stress and tension in my joints. Find out more and shop the balm here.
- Tanezumab safe, effective for chronic lower-back pain treatment, study findson June 19, 2020 at 10:37 am
A new drug, tanezumab, appears to reduce back pain, according to a study published Friday by the journal Pain.
- Inflammatory Pain Relief That Targets Delta Opioid Receptor May Have Fewer Side Effectson June 16, 2020 at 5:00 am
Researchers suggest the ability to target multiple receptors in pain-transmitting neurons for prolonged periods might provide effective and long-lasting pain relief ...
via Bing News